Our analysis suggests that the expression of RAPGEF4 in the cAMP signaling pathway is obviously decreased in ovarian cancer cells with stable knockdown of NOP2 expression compared to control cells (Table 3). Here, RAPGEF4 is linked to ovarian cancer.